Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EOC202 plus pembrolizumab versus placebo plus pembrolizumab in advanced head and neck squamous cell carcinoma
CTR20222961Phase 2Active
- Sponsor
- EOC Pharma
- Start
- Nov 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of eftilagimod alpha, pembrolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by EOC Pharma. Started Nov 2022; status: active.
02
Drugs
eftilagimod alphapembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20222961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222961.